Theralase Technologies Inc. V.TLT

NMIBC Patients talk treatments !

[Oden6570]

William63 Feb 15, 2024 • 10:01 AM

 

I was reading up on this as my good friend is going through this too. He says his is failed BCG Cis so not sure if that is close enough to what you are describing.

He lives near Toronto so his plan is to try the TLD one in that very excellent list as his urologist mentioned that it is one of the few that has some one or two and done options. As in, some people get the treatment and are effectively cured on the first treatment. Something like a third. So if he tries it and responds he doesn't have to commute repeatedly for the other drugs which are frequent bladder instillations. His master plan is to try the TLD if he can get on with the trial. Apparently if you are going to be one of those one and possibly cured long term responders you have a good chance of knowing that based on the results after 6 months. So then he thought he would ask about leaving the trial at 6 m if not responding and then joining another trial. Sounds complicated but that is his current thinking.

I got the pathology from my latest TURPT - Bladder cancer (inspire.com)

[Eoganacht]

This is an excellent illustration of the Ruvidar PDT advantage. It seems to me every BCG-unresponsive NMIBC patient would want to take a shot on a single treatment that gives them a 30% chance of a complete cure. Also I can't see why every urological oncologist wouldn't wanr to give their ailing patients this oopportunity. It's completely safe and if the patient doesn't respond you

[stocksnbonds458]

Since the Ruvidar treatment is so minimally invasive, at some point in the future would not multiple treatments given over the course of time increase that CR rate significantly higher than 30% for most any type of cancer the treatment is indicated for? 

[Eoganacht]

Given the new optional maintenance treatment, we may be about to find out: Optional Maintenance Study II Treatment - Patients currently receive a mandatory maintenance Study II Treatment at 180 days; however, this has been optimized to allow optional maintenance Study II Treatments, at the discretion of the Principal Investigator ("PI") based on the patient's response. For patients

[Yajne]

Great points Eogan, and shows further potential to increase the CR percentages. Curious as to how the timeline would work for non-CR patients who then become CR after receiving a maintenance Study II Treatment. I assume the 'durable response' clock would start ticking at 90 days when they first achieve CR.